LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Utility of Stool PCR for the Diagnosis of COVID-19: Comparison of Two Commercial Platforms.

    Szymczak, Wendy A / Goldstein, D Yitzchak / Orner, Erika P / Fecher, Roger A / Yokoda, Raquel T / Skalina, Karin A / Narlieva, Momka / Gendlina, Inessa / Fox, Amy S

    Journal of clinical microbiology

    2020  Volume 58, Issue 9

    Abstract: ... for greater than 4 weeks, suggesting that stool may hold utility as an additional source for diagnosis ... for detection of viral RNA in stool specimens and compared performance. We utilized remnant stool specimens ( ... symptom-onset in most patients. In contrast, SARS-CoV-2 can be detected in the stool of some patients ...

    Abstract The ability to detect SARS-CoV-2 in the upper respiratory tract ceases after 2 to 3 weeks post-symptom-onset in most patients. In contrast, SARS-CoV-2 can be detected in the stool of some patients for greater than 4 weeks, suggesting that stool may hold utility as an additional source for diagnosis. We validated the Cepheid Xpert Xpress SARS-CoV-2 and Hologic Panther Fusion real-time RT-PCR assays for detection of viral RNA in stool specimens and compared performance. We utilized remnant stool specimens (
    MeSH term(s) Betacoronavirus/genetics ; COVID-19 ; COVID-19 Testing ; COVID-19 Vaccines ; Clinical Laboratory Techniques/methods ; Clinical Laboratory Techniques/standards ; Clinical Laboratory Techniques/statistics & numerical data ; Coronavirus Infections/diagnosis ; Feces/virology ; Humans ; Limit of Detection ; Pandemics ; Pneumonia, Viral/diagnosis ; Polymerase Chain Reaction/methods ; Polymerase Chain Reaction/standards ; Polymerase Chain Reaction/statistics & numerical data ; RNA, Viral/analysis ; RNA, Viral/genetics ; Reproducibility of Results ; SARS-CoV-2
    Chemical Substances COVID-19 Vaccines ; Covid-19 aAPC vaccine ; RNA, Viral
    Keywords covid19
    Language English
    Publishing date 2020-08-24
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/JCM.01369-20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Utility of Stool PCR for the Diagnosis of COVID-19: Comparison of Two Commercial Platforms

    Szymczak, Wendy A / Goldstein, D Yitzchak / Orner, Erika P / Fecher, Roger A / Yokoda, Raquel T / Skalina, Karin A / Narlieva, Momka / Gendlina, Inessa / Fox, Amy S

    J. clin. microbiol

    Abstract: ... positive by both assays (6.9%). The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR-negative ... for greater than 4 weeks, suggesting that stool may hold utility as an additional source for diagnosis ... for detection of viral RNA in stool specimens and compared performance. We utilized remnant stool specimens (n ...

    Abstract The ability to detect SARS-CoV-2 in the upper respiratory tract ceases after 2 to 3 weeks post-symptom-onset in most patients. In contrast, SARS-CoV-2 can be detected in the stool of some patients for greater than 4 weeks, suggesting that stool may hold utility as an additional source for diagnosis. We validated the Cepheid Xpert Xpress SARS-CoV-2 and Hologic Panther Fusion real-time RT-PCR assays for detection of viral RNA in stool specimens and compared performance. We utilized remnant stool specimens (n = 79) from 77 patients with gastrointestinal symptoms. Forty-eight patients had PCR-confirmed COVID-19, and 29 either were nasopharyngeal/oropharyngeal PCR negative or presented for reasons unrelated to COVID-19 and were not tested. Positive percent agreement between the Cepheid and Hologic assays was 93% (95% confidence interval [CI]: 81.1% to 98.2%), and negative percent agreement was 96% (95% CI: 89% to 0.99%). Four discrepant specimens (Cepheid positive only, n = 2; Hologic positive only, n = 2) exhibited average cycle threshold (CT ) values of >37 for the targets detected. Of the 48 patients with PCR-confirmed COVID-19, 23 were positive by both assays (47.9%). For the negative patient group, 2/29 were positive by both assays (6.9%). The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR-negative patients were SARS-CoV-2 IgG positive. Our results demonstrate acceptable agreement between two commercially available molecular assays and support the use of stool PCR to confirm diagnosis when SARS-CoV-2 is undetectable in the upper respiratory tract.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #628838
    Database COVID19

    Kategorien

  3. Article ; Online: Utility of Stool PCR for the Diagnosis of COVID-19

    Szymczak, Wendy A. / Goldstein, D. Yitzchak / Orner, Erika P. / Fecher, Roger A. / Yokoda, Raquel T. / Skalina, Karin A. / Narlieva, Momka / Gendlina, Inessa / Fox, Amy S.

    Journal of Clinical Microbiology

    Comparison of Two Commercial Platforms

    2020  Volume 58, Issue 9

    Abstract: ... were positive by both assays (6.9%). The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR ... assays for detection of viral RNA in stool specimens and compared performance. We utilized remnant stool ... commercially available molecular assays and support the use of stool PCR to confirm diagnosis when SARS-CoV-2 ...

    Abstract ABSTRACT The ability to detect SARS-CoV-2 in the upper respiratory tract ceases after 2 to 3 weeks post-symptom-onset in most patients. In contrast, SARS-CoV-2 can be detected in the stool of some patients for greater than 4 weeks, suggesting that stool may hold utility as an additional source for diagnosis. We validated the Cepheid Xpert Xpress SARS-CoV-2 and Hologic Panther Fusion real-time RT-PCR assays for detection of viral RNA in stool specimens and compared performance. We utilized remnant stool specimens ( n = 79) from 77 patients with gastrointestinal symptoms. Forty-eight patients had PCR-confirmed COVID-19, and 29 either were nasopharyngeal/oropharyngeal PCR negative or presented for reasons unrelated to COVID-19 and were not tested. Positive percent agreement between the Cepheid and Hologic assays was 93% (95% confidence interval [CI]: 81.1% to 98.2%), and negative percent agreement was 96% (95% CI: 89% to 0.99%). Four discrepant specimens (Cepheid positive only, n = 2; Hologic positive only, n = 2) exhibited average cycle threshold ( C T ) values of >37 for the targets detected. Of the 48 patients with PCR-confirmed COVID-19, 23 were positive by both assays (47.9%). For the negative patient group, 2/29 were positive by both assays (6.9%). The two stool PCR-positive, nasopharyngeal/oropharyngeal PCR-negative patients were SARS-CoV-2 IgG positive. Our results demonstrate acceptable agreement between two commercially available molecular assays and support the use of stool PCR to confirm diagnosis when SARS-CoV-2 is undetectable in the upper respiratory tract.
    Keywords Microbiology (medical) ; covid19
    Language English
    Publisher American Society for Microbiology
    Publishing country us
    Document type Article ; Online
    ZDB-ID 390499-4
    ISSN 1098-660X ; 0095-1137
    ISSN (online) 1098-660X
    ISSN 0095-1137
    DOI 10.1128/jcm.01369-20
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top